Eloxx Pharmaceuticals announced that Robert (“Bob”) Ward has been appointed chairman of the board of directors of Eloxx, and chief executive officer. Bob joins at a critical inflection point for Eloxx as the company advances its lead candidate ELX-02, a novel translational read-through inducing drug (TRID), through the completion of Phase 1 clinical trials and navigates its transition from a private to a public company.   Mr. Ward comes with more than 30 years of experience as a global b...